TITLE

Chlorphen-12 antihistamine rolled out by KVK

PUB. DATE
February 2011
SOURCE
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p38
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the distribution of the Chlorphen-12, an antihistamine, from KVK Tech Inc. which has been approved by the U.S. Food and Drug Administration (FDA).
ACCESSION #
59994603

 

Related Articles

  • Determination That WILPO (phentermine hydrochloride) Tablets, 8 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Kux, Leslie // Federal Register (National Archives & Records Service, Office of;02/13/2012, Vol. 77 Issue 29, p7583 

    The article provides information on a notice issued by the U.S. Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services to the U.S.-based drug manufacturer KVK-Tech Inc. regarding its WILPO, a phentermine hydrochloride tablet. It states that the FDA will approve...

  • Schering readies Clarinex launch.  // Medical Marketing & Media;Jan2002, Vol. 37 Issue 1, p8 

    Focuses on the approval of Food and Drug Administration on the marketing of non-sedating antihistamine clarinex in the U.S. Price offering of the drug; Comparison on the efficacy of clarinex with claritin.

  • Hay fever drug to be banned by the FDA. Josefson, Deborah // BMJ: British Medical Journal (International Edition);1/25/97, Vol. 314 Issue 7076, p248 

    Reports on plans by the United States Food and Drug Administration to ban a popular antihistamine terfenadine. Side effects; Cases of serious cardiac dysrythmias associated with the drug; Alternatives.

  • Retailers prepare for Claritin switch, productive cough-cold season. Johnsen, Michael // Drug Store News;7/22/2002, Vol. 24 Issue 9, p39 

    Talks about the imminent switch of the second-generation, non-sedating antihistamine Claritin. Support given by the U.S. Food and Drug Administration to Claritin as an over-the-counter treatment for chronic idiopathic urticaria; Issue concerning the Claritin switch; Expected result of the...

  • FDA approvals.  // Geriatrics;Feb96, Vol. 51 Issue 2, p23 

    Reports that Nisoldipine (Sular), an extended-release antihypertensive and Loratidine (Claritin), an antihistamine for hives have been approved safe by the United States Food and Drug Administration.

  • FDA looking at antihistamines promoting cancer. Conlan, Michael F. // Drug Topics;6/13/94, Vol. 138 Issue 11, p109 

    Reports on the Food & Drug Administration's efforts to duplicate the results of a Canadian study that suggests that three prescription antihistamines stimulate the growth of cancer tumors. Decision on the labeling of the drugs involved.

  • FDA moves antihistimines toward OTC use.  // Drug Utilization Review;Jul2001, Vol. 17 Issue 7, p56 

    Enumerates various prescription antihistamine drugs that were approved by the United States Food and Drug Administration as safe for over-the-counter use. Loratadine; Cetirizine; Fexofenadine.

  • Topical Benadryl warning.  // Monthly Prescribing Reference;Jun2010, Vol. 26 Issue 6, pA.17 

    The article reports on the warning given by the Food and Drug Administration (FDA) to consumers regarding the side-effects of swallowing diphenhydramine Benadryl Extra Strength Itch Stopping Gel from McNeil Consumer & Specialty in the U.S.

  • With a Little Help From a Pill. Walsleben, Joyce // New York;6/9/2014, Vol. 47 Issue 13, p24 

    The article explains how to make the most of some quick-fix sleep aids. Topics discussed include the Rozerm which should be taken 30 minutes before bed according to the U.S. Food Drug and Administration (FDA), Ambien, the most common drug with zolpidem that lasts about 6 hours and Nyquil which...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics